Arcutis Biotherapeutics Shares Jump After FDA OKs Skin-Condition Treatment
By Ben Glickman
Shares of Arcutis Biotherapeutics rose late Friday after the company's treatment for a skin condition was approved by the Food and Drug Administration.
The stock was up 18% to $2.89 in after-hours trading, following a 3.9% drop at Friday's close. Shares are down about 84% this year.
Zoryve topical foam has been approved for the treatment of seborrheic dermatitis, a skin condition which mostly affects the scalp, the Westlake Village, Calif.-based dermatology company said.
A cream form of Zoryve was already approved by the FDA for the topical treatment of plaque psoriasis in patients 6 years of age and older. Net product revenues for the cream were $8.1 million in the third quarter, Arcutis reported last month.
Arcutis said it plans to make the topical foam widely available by the end of next month.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 15, 2023 17:58 ET (22:58 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk